# CBD Safety Research: Reviews and Testing Standards 2026 > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cbd-safety-research-articles-february-26-2026/ > **Published:** 2026-02-26T11:22:47-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T12:01:46-04:00 > **Clinical Summary:** Explore CBD safety research with product reviews and testing standards from February 26, 2026. Learn about third-party verification and formulation details. --- In the Mix** 8 articles reviewed and scored below the CED clinical relevance threshold of 40. Organized by topic below. Some may still be relevant to your situation. Jump to topic [CBD (3)](#cbd)[Policy (5)](#policy) CBD (3 articles) #25 CBDSafetyResearch [Medterra CBD Review: Products, Testing Standards & Our Experience – Forbes](https://www.forbes.com/health/cbd/medterra-review/) Medterra provides certificates of analysis for its CBD products, though ingredient information on product pages is limited. Third-party testing documentation is available on the company website to verify cannabinoid content and purity. While Medterra makes certificates of analysis accessible to consumers, the sparse ingredient labeling on product pages may limit informed decision-making about formulation details. [Read more →](https://www.forbes.com/health/cbd/medterra-review/) #20 CBDSafetyResearch [R&R CBD Review: Products, Testing Standards & Our Experience – Forbes](https://www.forbes.com/health/cbd/r-and-r-review/) A Forbes review evaluates R&R CBD’s product line, which combines CBD with other cannabinoids in formulations both with and without THC to address various health needs. The assessment examines the company’s testing standards and overall product quality for consumers seeking multi-cannabinoid options. R&R CBD’s multi-cannabinoid product formulations with varying THC content may offer broader therapeutic potential than isolated CBD alone, though efficacy depends on individual cannabinoid profiles and third-party verification standards. [Read more →](https://www.forbes.com/health/cbd/r-and-r-review/) #18 CBDSafety [CBDistillery Review: Products, Testing Standards & Our Experience – Forbes](https://www.forbes.com/health/cbd/cbdistillery-review/) CBDistillery products undergo third-party laboratory testing to verify cannabinoid content and potency, with products containing measurable cannabinoids and terpene profiles. Testing standards ensure consumers receive accurate information about cannabinoid concentrations and additional plant compounds in each product. Third-party verification of cannabinoid content and terpene profiles provides transparency regarding product composition and potency. [Read more →](https://www.forbes.com/health/cbd/cbdistillery-review/) [↑ back to top](#itm-top) Policy (5 articles) #8 PolicySafety [Arizona senator proposes ‘public nuisance’ bill for marijuana** smell – YouTube](https://www.youtube.com/watch?v=iaSwEwmQwuU) An Arizona senator has proposed legislation to classify excessive marijuana smoke and odor as a public nuisance, citing potential harm to neighboring residents. The bill has received mixed reactions from stakeholders regarding the feasibility and implications of regulating cannabis-related odor in residential areas. The proposal to regulate marijuana odor as a public nuisance raises questions about enforcement standards and the balance between cannabis users’ rights and community impacts in states with legal markets. [Read more →](https://www.youtube.com/watch?v=iaSwEwmQwuU) #5** PolicyIndustry [The Des – In all, 24 states have passed legislation to legalize marijuana** for recreational use …](https://www.facebook.com/DesMoinesRegister/photos/in-all-24-states-have-passed-legislation-to-legalize-marijuana-for-recreational-/1343846844447153/) Twenty-four states have now legalized marijuana for recreational use, with several states neighboring Iowa adopting similar legislation. The expansion of recreational cannabis availability across multiple states reflects shifting regulatory approaches to [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) across the United States. The continued expansion of recreational marijuana legalization across state lines raises important questions about standardization of cannabis products, potency labeling, and clinical oversight in an increasingly fragmented regulatory landscape. [Read more →](https://www.facebook.com/DesMoinesRegister/photos/in-all-24-states-have-passed-legislation-to-legalize-marijuana-for-recreational-/1343846844447153/) #3** PolicyIndustry [Madison Township Zoning Commission OKs site plan for marijuana** facility](https://www.news-herald.com/2026/02/26/madison-township-zoning-commission-oks-site-plan-for-marijuana-facility/) A Madison Township Zoning Commission has approved a site plan for a marijuana cultivation facility in the area. The approval moves forward the development of the cannabis growing operation within the township’s jurisdiction. Local zoning approval for cannabis cultivation facilities continues to expand infrastructure for legal marijuana production and distribution. [Read more →](https://www.news-herald.com/2026/02/26/madison-township-zoning-commission-oks-site-plan-for-marijuana-facility/) #2** PolicySafetyIndustry [Union County officials seize drugs, candy-branded THC** products in multi-agency operation](https://www.wcnc.com/article/news/crime/multi-agency-operation-drugs-thc-products-seized-union-county/275-570675b7-f72b-4237-9010-dc1c988893b9) Law enforcement in Union County conducted a multi-agency operation targeting illegal THC retailers, resulting in the seizure of over $100,000 in products including candy-branded THC items. The operation focused on enforcing regulations against unauthorized drug sales at THC retail locations. Multi-agency enforcement actions targeting unregulated THC retailers highlight ongoing challenges with product safety oversight and compliance in cannabis retail markets. [Read more →](https://www.wcnc.com/article/news/crime/multi-agency-operation-drugs-thc-products-seized-union-county/275-570675b7-f72b-4237-9010-dc1c988893b9) #0** PolicyIndustry [Here’s Why Tenet Healthcare (THC**) is a Strong Value Stock – Yahoo Finance](https://finance.yahoo.com/news/heres-why-tenet-healthcare-thc-144004904.html) This article discusses Tenet Healthcare’s stock valuation metrics and investment potential based on financial analysis rather than cannabis-related [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/). The piece is not relevant to [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) or [cannabinoid science](https://cedclinic.com/cannabis-varieties-differentiation-cannabinomics/). This article about Tenet Healthcare’s stock performance does not contain clinical or scientific information about cannabis or cannabinoids. [Read more →](https://finance.yahoo.com/news/heres-why-tenet-healthcare-thc-144004904.html) [↑ back to top](#itm-top) See the top-ranked articles at [cedclinic.com/category/cannabis-news/](https://cedclinic.com/category/cannabis-news/) Digest-Level Clinical Commentary Dr. Caplan’s Take Clinical Reflection These items reflect a field in transition: while product quality and testing standards are increasingly professionalized (items 2-3), the broader regulatory landscape remains fragmented and reactive rather than evidence-driven, with policy discussions centered on nuisance complaints and facility zoning rather than clinical outcomes or pharmacological research. As a clinician, I note that none of these nine items address patient safety data, drug interactions, or therapeutic efficacy, suggesting that [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practice continues to advance ahead of the policy and industrial frameworks that should support it. The preponderance of industry and policy content over clinical evidence signals that my patients will have easier access to tested products in more states, but I’ll have fewer contemporary guidelines to inform dosing and monitoring practices. Clinical Perspective Clinical Perspective These items reflect two parallel developments in cannabis: expanding regulatory fragmentation across states with recreational legalization, and increased focus on product standardization through third-party testing. For clinicians, the proliferation of unregulated THC products and varying state policies creates ongoing challenges in counseling patients about product safety and legal status. The emphasis on testing standards represents a positive trend toward verifiable cannabinoid content, though clinical evidence regarding CBD efficacy and safety remains limited, as suggested by the articles scoring below the relevance threshold. Broad Topic Tags CBDPolicyProduct SafetyIndustry Regulation[Cannabis Legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+In+the+Mix%3A+8+More+Articles+%E2%80%94+February+26%2C+2026+%40drcaplan&url=) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=) [🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+In+the+Mix%3A+8+More+Articles+%E2%80%94+February+26%2C+2026+--+via+%40drcaplan.bsky.social+) [📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/) [📝 Read more on Substack](https://substack.com/@doctorapproved) [🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [In the Mix: 20 More Articles — March 08, 2026](https://cedclinic.com/cannabis-pediatric-exposure-toxicity-march-08-2026/) - [In the Mix: 5 More Articles — March 07, 2026](https://cedclinic.com) - [In the Mix: 5 More Articles — March 07, 2026](https://cedclinic.com/cannabis-industry-regulatory-challenges-2026/) Further Reading CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) Evidence Watch[`Cannabinoid Clinical Trials: CBD Cortical Excitability Study`](https://cedclinic.com/cannabidiol-lacks-intrinsic-anti-epileptic-properties-trial/) Cannabis Policy Wire[Policy Watch: 20 Regulatory Updates — March 10, 2026](https://cedclinic.com/dea-scheduling-synthetic-opioids-regulatory-updates-2026/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence Medterra CBD Review: Products, Testing Standards & Our Experience – Forbes An in-depth review of Medterra CBD products focusing on testing standards and third-party verification for consumer safety. Read the Medterra CBD Review [Hemp products had illegal THC amounts, mold, pesticides, and carcinogens, investigation finds](https://cedclinic.com/hemp-product-contamination-risks-thc-mold-pesticides/) Investigation reveals safety concerns in hemp products including illegal THC levels and contaminants, highlighting the need for rigorous testing. [Explore the Investigation Findings](https://cedclinic.com/hemp-product-contamination-risks-thc-mold-pesticides/) Charlotte’s Web CBD Review: Products, Testing Standards & Our Experience – Forbes Review of Charlotte’s Web CBD products with emphasis on quality control, testing standards, and consumer transparency. Read the Charlotte’s Web Review ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).